01/16/2015 Vicus Therapeutics Announces Safety and Survival Benefit of VT-122 in Combination with Anti-Cancer Therapies for Advanced Liver and Pancreatic Cancers
10/31/2014 Vicus Therapeutics Issued Key Japanese Patent Covering the Composition of Matter of VT-122 into 2025
09/05/2014 Vicus Therapeutics Announces Phase II Data Demonstrating Overall Survival Benefit with VT-122 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
HOME | ABOUT | PLATFORM | DEVELOPMENT | NEWS | CONTACT
Copyright © 2014 Vicus Therapeutics All Rights Reserved.